Sucampo Reports Continued Strong Performance for Fourth Quarter and Full Year 2015
Mar 08, 2016 11:30 am UTC| Business
Results Driven by Continued AMITIZA Growth and R-TECH UENO Acquisition Company Reiterates 2016 Guidance Company to Host Conference Call Today at 8:30 a.m. EST ROCKVILLE, Md., March 08, 2016 -- Sucampo...
Hawaiian Telcom Reports Fourth Quarter and Full Year 2015 Results
Mar 08, 2016 11:00 am UTC| Business
Achieved full year revenue growth of $2.7 millionDelivered full year consumer strategic revenue(1) growth of 21 percent Grew Hawaiian Telcom TV subscribers by 27.6 percent in 2015Increased full year business strategic...
Mar 08, 2016 10:51 am UTC| Business
Albany, NY, March 08, 2016 -- A new report has been published by Transparency Market Research on the global pressure relief devices market. According to the report, the global pressure relief devices market is expected...
Mar 08, 2016 10:46 am UTC| Business
Albany, NY, March 08, 2016 -- The European LiFi (Light Fidelity) Technology Industry 2016 Market Research Report is a professional and in-depth study on the current state of the LiFi (Light Fidelity) Technology...
Moody's: China's robust railway spending is credit positive for China Railway Construction
Mar 08, 2016 10:43 am UTC| Research & Analysis Business
Moodys Investors Service says that the Chinese governments (Aa3 negative) plan to continue spending strongly on railway construction in 2016 is credit positive for China Railway Construction Corporation Limited (CRCC) and...
Mar 08, 2016 10:30 am UTC| Business
San Francisco, March 08, 2016 -- The probiotics market is emerging as one of the fastest growing market globally. In 2013, the global probiotics market was estimated as a value of USD 32.06 billion and is expected...
Nexvet Announces Successful Completion of NV-01 Pilot Field Study in Dogs With Osteoarthritis
Mar 08, 2016 10:30 am UTC| Business
DUBLIN, Ireland, March 08, 2016 -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced the successful completion of its pilot field study for ranevetmab* (NV-01), the Company's anti-nerve...